Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HUTCHMED (China) ( (HK:0013) ) has issued an announcement.
HUTCHMED (China) Limited announced that all resolutions proposed at its Annual General Meeting on May 13, 2025, were passed, including the re-election of directors and the re-appointment of auditors. The approval of these resolutions supports the company’s governance and operational continuity, potentially strengthening its position in the biopharmaceutical industry.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.